Fig 1.
Characterization targets flowchart for T. cruzi multilocus conventional PCR and expected sizes of amplified products, based in four molecular markers [28].
Table 1.
Primers for Trypanosoma cruzi molecular typing.
Table 2.
Epidemiological characteristics of studied patients.
Table 3.
Panel of the molecular targets and DTUs identified in the T. cruzi isolates from blood cultures.
Fig 2.
Representative agarose gels showing T. cruzi target genes amplified by multilocus conventional PCR.
A) SL-IRac target (150/157bp/200bp). Lanes: 1- TcI (Dm28c), 2- TcII (Y), 3- TcIV (INPA4167), 4–15 –Patient samples; B) SL-IR I and II target (300/350bp). Lanes: 1- TcI (Dm28c), 2- TcII (Y), 3–15 –Patient samples, 16- TcI (Dm28c), 17- TcII (Y);, C) 24Sα rDNA target (125/140bp). Lanes: 1- TcII (Y), 2- TcIII (INPA3663), 3–15 –Patient samples; D) A10 target (525/580bp). Lanes: 1- TcII (Y), 2- TcVI (CL), 3–13 –Patient samples. MW, molecular weight; NC, negative control; bp, base pairs.
Fig 3.
Spatial distribution of T. cruzi DTUs from INI cohort Chagas disease patients according to their place of birth, except for the case of congenital transmission that was located according to his mother place of birth (Cachoeira do Sul, RS).
This map was created using QGIS version 3.4 software and cartographic bases maps modified from open access by the Brazilian Institute of Geography and Statistics, IBGE (https://www.ibge.gov.br/geociencias/downloads-geociencias.html). ND, not detected.
Table 4.
Clinical, epidemiological, follow-up, outcome, and DTU classification of studied patients.